230.7K views | +344 today

Livongo to offer Voluntis’ Insulia for type 2 diabetes to improve medication adherence


Livongo to offer Voluntis’ Insulia for type 2 diabetes to improve medication adherence
No comment yet.



Yesitis connecte les étiquettes en série : RFID et NFC - au coeur du médicament connecté pour apporter de nouveaux services et de la sécurité

No comment yet.

Le digital au service de la #SERIALISATION du médicament et de la #supplychain #pharma


C.S.P. Centre Spécialités Pharmaceutiques, leader dépositaire pharmaceutique, a lancé DIGITAL CSP, plateforme de service numérique, pour accompagner
No comment yet.

Creating the Perfect Healthcare Digital Marketing Campaign


Learn how to create a digital marketing campaign specifically for healthcare organizations and see an example built-out campaign.
No comment yet.

10 ways healthcare companies are testing Instagram


1. Medtronic (Corporate)

The medical device company, which develops insulin pumps for diabetes patients, has more than 16,000 followers. Wendy Blackburn, EVP of Intouch Solutions, said Instagram makes sense for diabetes marketing, since it has always been a disease category that is active on social media and tends to have a broad age range of patients.

2. Team Novo Nordisk (Corporate) 

“Racing to inspire, educate and empower everyone affected by diabetes” is the tagline of Novo Nordisk's diabetes pro cycling team. This account has more than 73,000 followers and close to 2,000 posts.

3. #BreatheBoldly(Campaign)

In honor of the late Leonard Nimoy, who famously played Mr. Spock from “Star Trek,” Philips Healthcare and the COPD Foundation launched the #BreatheBoldly campaign to raise awareness of COPD in November. Celebrities such as actress Whoopi Goldberg, actor Vince Vaughn, and reality TV star Melissa Gorga posted videos on their Facebook and Instagram pages to show the challenges of suffering from the condition.

4. Flonase (Brand)

Facebook Health industry manager Danielle Salowski points to GlaxoSmithKline's over-the-counter allergy treatment Flonase as a good example of Instagram used well, showcasing vibrant seasonal imagery with related comments and information about how allergies affect people in the winter, spring, fall, and summer.

5. Pfizer (Corporate)

Blackburn doesn't recommend deleting comments, even when they are negative. She noted that Pfizer has a lot of trolls on its Instagram page, but doesn't delete them. “There will always be trolls and haters,” she said. “Deleting sends the wrong message because you're on there to engage to begin with.”

See also: How can drugmakers tell better stories? Try Instagram

6. Bayer4Animals (Corporate) 

According to a study by BarkBox, dog owners in the U.S. on average post one photo or talk about their dog on social media six times a week. Bayer Animal Health targets pet owners and animal lovers with engaging animal photos and information about keeping them healthy.

7. Tylenol (Brand)

Like Flonase, Johnson & Johnson's Tylenol ties different moments throughout their year with content that tells a story through that lens, noted Salowski. “What I like about that is people know what to expect when they see content from Tylenol,” she said. “That's how they're connecting and engaging, and they just do a beautiful job with their photography and taking advantage of the mobile format.”

8. Emily Maynard for Diclegis (Influencer)

In June, The Bachelor and The Bachelorette's Emily Maynard Johnson made a post about her experience taking Duchesnay USA's morning sickness pill Diclegis — including safety information. It is the drugmakers second attempt at leveraging a celebrity spokesperson's Instagram handle — following a less successful example with Kim Kardashian West in July 2015 — to reach its target audience of expectant mothers.

9. Novartis (Corporate)

Novartis' corporate Instagram page comprises a mix of images and videos showing their corporate history and milestones, social and humanitarian efforts, and the drugmaker's attention to education and training.

10. Sanofi (Corporate)

There are drugmakers like Sanofi that have created an Instagram handle but not yet activated it with posts.

No comment yet.

Inhalateurs connectés: Propeller Health ajoute Novartis à ses laboratoires partenaires


MADISON (Wisonsin) (TICpharma) - La société américaine Propeller Health a annoncé le 8 février un partenariat avec Novartis afin de développer un capteur sur mesure pour connecter l'inhalateur Breezhaler* à sa plateforme de traitement des données liées aux troubles respiratoires.

No comment yet.

Pour réussir sa transformation digitale, il faut s’être transformé soi-même


Les 40-50 ans avons vu démarrer l’Internet, lancé des régies digitales et des sites de marques avec des modems trop lents.
No comment yet.

Bayer expanding its digital health accelerator program to San Francisco


The German life sciences company plans to bring its accelerator program for digital health startups to San Francisco. It's now available in Berlin, Moscow, and Shanghai among other places.
No comment yet.

Asthma UK calls for smart planning on smart inhaler adoption


Smart inhalers are poised to enter the UK healthcare system with the potential to transform care for people with asthma
No comment yet.

Gilead to use dating sites, Tumblr, and Snapchat in Truvada strategy


The drugmaker is planning a commercial boost for its HIV-prevention drug.
No comment yet.

MIT & GlaxoSmithKline launch flu tracking app Flumoji


Pharmaceutical giant GlaxoSmithKline and MIT Connection Science have launched a new flu app called Flumoji to help users track symptoms & share that information with researchers working to improve disease surveillance.

Cases of the flu have increased nationally as the season begins to hit its usual peak. Tracking the activity of such an ubiqutious disease can help public health officials guide limited resources to the areas where they could get the most bang for their buck.

We’ve seen interesting uses of digital health for flu tracking in recent years, ranging from medical apps to guide flu treatment to the use of social media and internet searches to track activity. Flumoji is an Android app that includes educational material about the flu as well as symptom tracking features, which includes collection of data already being captured by the phone:

…the Flumoji app tracks a variety of real-time data from a user’s phone in order to detect fluctuations in a user’s activity levels, social levels, and general routine. These fluctuations are used to predict whether a user is experiencing a flu-like outbreak. Real-time data is only collected during the flu season.
No comment yet.

Why Pharma Companies Should Embrace Digital Health Startups & Vice Versa


While most healthcare stakeholders are eager to embrace digital health, the pharmaceutical sector has been somewhat reluctant to join the digital health bandwagon. Some of the forward-thinking pharma companies are just now awakening to the opportunity for digital health to strengthen their businesses (see “The Pharma Digital Health Accelerator Club”;  


For pharma companies to realize digital health’s potential as quickly as possible, they should seek out and partner with technology startups focused on digital health innovation. Savvy startups should be receptive to these collaborations, as there are major benefits to them from working with pharma.  

By embracing digital health tools alone or in combination with medications, pharmaceutical companies can:


  • Improve outcomes
  • Build connections to patients
  • Strengthen branding


As with many disruptive innovations, digital health requires the development of novel business models and partnerships to succeed. The most effective way for pharmaceutical companies to achieve these benefits is to partner with multiple, compatible digital health startups, and to have these startups build innovative patient and provider-facing digital health solutions on behalf of their pharma partners.


When pharma comes courting, a savvy digital health startup should be receptive. It can benefit enormously by working with a drug company. One of the biggest benefits: access to a pharma company’s substantial sales and marketing networks. Selling products into the healthcare system can be extremely difficult because of the wide variety of physician practice models and healthcare procurement processes. Startups often lack the infrastructure needed to reach customers and, therefore, have trouble scaling up sales. Many fail as a result. Teaming with pharma and tapping into their extensive marketing infrastructures and distribution channels will help digital startups gain traction far faster than they could on their own.


Which pharmas will embrace partnerships?



No comment yet.

Propeller and Novartis collaborate to develop add-on sensor for COPD treatments


Digital respiratory health management company Propeller Health is collaborating with Novartis to develop a custom add-on sensor for the Swiss pharmaceutical company’s Breezhaler inhaler, which is used for Novartis’s portfolio of COPD treatments. The partnership will be focused in Europe.
No comment yet.

Année 2016 en demi-teinte pour les grands laboratoires #pharma


Génériques et remboursements moins généreux érodent le
No comment yet.

Lifetime Trends in Biopharmaceutical Innovation Recent Evidence and Implications


This report profiles the NASs launched in the U.S. over the past 20 years and measures the length of a molecule’s lifetime from patent filing to launch and eventual patent expiry. It also explores the significant variations in this lifetime when viewed by molecule characteristics such as therapy area, orphan drug status, and the type of companies involved in the development and marketing.

Take a look at some of the coverage from the event in The Scientist, American Journal of Managed Care, and The Pharma Letter.

rob halkes's curator insight, February 7, 5:27 AM

Relevant Insights into the development in lifetime characteristics of biopharmaceutical substances: only relative few outliers that make a quick retunr about 1$ billion a year (within 5 years after launch) Modest levels of average return (less than $100 billion) a year for 62% of launches in the past 20 years. The commercial returns for a small number of outlier molecules areoutsized but rare, while a substantial number of molecules baing launches achive levels of commercial success that fall far below threshold levels of economic return.

Take a look at some of the coverage from the event in The Scientist, American Journal of Managed Care,

Infographie : tout savoir sur la pharmacovigilance


Pour bien comprendre la pharmacovigilance et montrer l'impact du social média monitoring, LexisNexis BIS a publié en ce début d'année une infographie.
No comment yet.

Rapport Deloitte sur la transformation digitale des PME en France


Facebook a commandé un rapport à Deloitte sur la transformation digitale des PME. Le constat est sans appel vis-à-vis des autres pays européens : les entre
No comment yet.

Will Pharma Companies Move to Branded Instagram Accounts?


Drugmakers have claimed their Instagram turf by launching corporate pages first then moving to unbranded and branded ones. Medtronic and Novartis are actively engaging on the platform through their corporate handles, each with more than 14,000 followers. Then there are companies such as Sanofi that have created a handle, but not yet activated it with posts, says Intouch Solutions EVP Wendy Blackburn.


[Read “Pharma on Instagram: How Top Drug Companies Use It Today & May Use It Tomorrow”;]


UCB global multichannel engagement solutions lead Greg Cohen says “I've noticed pharma companies have grabbed the Instagram names for their products, but there are no posts yet,” he continues. “They're probably getting them set up and holding them in case they decide to move into it.”


What makes Instagram so potentially valuable to pharma and healthcare marketers is its visual story-telling capability. As Salowski notes, it is “incredibly sticky” when it comes to engagement. The average Instagram user spends 21 minutes per day in the app, and users upload more than 95 million photos per day, which garner more than 3.5 billion likes.


Thus, Instagram allows companies to not just break down complicated medical issues, but also “distill them into bite-sized components, which patients can consume more easily,” Cohen explains. “Users can either learn and teach themselves or share them with their networks, because the highly visual nature makes it easy for them to share their stories.”


“Instagram makes more sense for disease categories for younger people,” Blackburn explains. “Diabetes is where I see the biggest opportunity and activity, because it has always been a social disease category. It's not right for Alzheimer's or Parkinson's right now,” she adds.


As with their presence on other social media platforms, drugmakers on Instagram face the challenge of regulatory compliance. This is no small hurdle, given how the FDA continues to fine-tune guidelines about safety information within limited-character formats. Instagram has a character limit of 2,200, which affords more flexibility than Twitter's 140 characters, but still may not be enough.


If nothing else, Duchesnay's experience with Kardashian West reinforced the importance of hewing to the prescribed rules.


Another concern drugmakers may have is how to deal with negative comments and online trolls. While companies can disable comments altogether, they're wary of limiting the back and forth with patients, physicians, and caregivers. That's why Blackburn singles out Pfizer's corporate Instagram page, thought to be one of the most skilled in moderating, deflecting, and otherwise dealing with negative comments.


“Pfizer can delete the comments, but they don't,” she notes. “There are always going to be trolls and haters. Deleting them sends the wrong message, because you're there to engage. At the same time, you can't play into the game of responding to every troll. Ignore the ones that came on to bait you.”


Further Reading:

  • “Instagram Offers Pharma Marketers Better Tools Than Facebook to Block Those "Nasty" Comments”; 
  • “Now May Be the Time for Pharma to Get Serious About Instagram”; 
  • “Should #Pharma Consider Instagram for Promotion & Patient Engagement?”;
Pharma Guy's curator insight, February 6, 1:15 PM

Right now, there are NO Rx branded Instagram accounts.

axiomzaftig's comment, February 6, 10:05 PM

Automédication : les laboratoires veulent en profiter


SANTÉ - L’automédication progresse en France, pour la deuxième année consécutive. Et les industriels comptent bien se saisir du marché. 
No comment yet.